People wit
Internal Medicine
2021-03-04

People with SARS-CoV-2 antibodies have a strong response to a single dose of mRNA COVID-19 vaccine: Study

Healthcare workers with previous coronavirus disease 2019 (COVID-19) infection, based on laboratory-confirmed serology testing, had higher antibody titre responses to a single dose of the mRNA COVID-19 vaccine than those who were not previously infected, according to a study published in JAMA. Antibody titres started peaking at 7 days in people who had been previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and at 14 days, higher titres and neutralisation were achieved compared with people who did not previously contract the virus. “Persons who have ha...

High Incid
Internal Medicine
2021-03-03

High Incidence of Kidney Injury That Leads to CKD After Heart Transplantation

Patients undergoing heart transplantation are at an increased risk of acute kidney injury that commo...

Reduction
Internal Medicine
2021-03-02

Reduction in COVID-19 patients requiring mechanical ventilation following national vaccination ...

Findings published in the US Centers for Disease Control and Prevention's (CDC) latest Morbidity and...

Videos from category: Cardiology

From Trial
13:26

From Trials to Bedside: Filling the Gaps in Implementing Evidence-based Care

AHA 2020
Coronary A
9:57

Coronary Artery Disease: What was new at ESC Congress 2020?

2020 Scientific Congress of th
State of t
8:34

State of the Science: The Six Pillars of Heart Failure Therapy

AHA 2020
A Polypill
13:09

A Polypill for Primary Prevention of Cardiovascular Disease in Intermediate Risk People: Results of the International Polycap Study (TIPS)-3

AHA 2020

Videos from category: Dermatology

Psoriasis
6:51

Psoriasis is a systemic disease

EADV 2020
New non-al
6:36

New non-allergenic, anti-inflammatory fragrance could be game changer for dry skin sufferers

EADV 2020
New Resear
4:08

New Research Reveals that Risky Sexual Behaviour and STIs are on the Rise Despite COVID-19 Pandemic

EADV 2020
New eviden
7:47

New evidence shows that systemic inflammation in psoriasis can be treated orally with a non-living strain of a commensal microbe

EADV 2020

Videos from category: Diabetology

Accumulate
8:58

Accumulated CV data from SGLT2i outcomes trials

EASD 2020
Remission
10:22

Remission of type 2 diabetes with return of insulin secretory function restores normal pancreas morphology

EASD 2020
Summary of
7:44

Summary of clinical and scientific topics discussed at EASD 2020 congress

EASD 2020
Effects of
11:28

Effects of empagliflozin on physical activity and compensatory appetite responses in people with type 2 diabetes: the SEESAW trial

EASD 2020

Videos from category: Gastroenterology

Duodenal m
11:01

Duodenal mucosal resurfacing shown to discontinue insulin treatment in majority of type 2 diabetes patients and aid weight loss

UEG 2020
Allergy-re
7:48

Allergy-related diseases and IBS

UEG 2020
How to seq
2:20

How to sequence advanced therapies in IBD - Evidence from clinical trials and real-world experience

ECCO 2020
A Next-Gen
3:06

A Next-Generation, Dual-Action Anti-Integrin Therapy for IBD

ECCO 2020

Videos from category: Hematology

Optimal Du
3:55

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

ASH 2020
Effect of
4:54

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin on Patients with Relapsed/Refractory Classical Hodgkin Lymphoma: Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

ASH 2020
Comprehens
14:08

Comprehensive summary of novel multiple myeloma data from ASH2020

ASH 2020
Novelties
8:45

Novelties on the treatment of Multiple Myeloma and Plasma Cell Disorders

ASH 2020

Videos from category: Internal Medicine

What is th
14:04

What is the role of transdermal fentanyl patches in management of cancer pain?

PAINWeek 2020
Which are
4:59

Which are the most promising new medications in phase 3 clinical trials for the treatment of painful large joint arthritis?

PAINWeek 2020
Towards a
8:42

Towards a better understanding of interstitial lung diseases associated with autoimmune rheumatic diseases - Optimising the monitoring and treatment of SSc-ILD

EULAR 2020
Controvers
3:07

Controversial issues in guidelines

ESH 2019

Videos from category: Oncology

Global Per
8:14

Global Perspectives on Breast Cancer Care during the COVID-19 Pandemic how BC was managed and lessons Learned

SABCS 2020
Omitting R
5:14

Omitting Radiation Therapy After Breast-Conserving Surgery May Not Impact 10-year Survival Rates for Older Patients With HR-positive Breast Cancer

SABCS 2020
Women Who
5:46

Women Who Undergo Mastectomy and Reconstructive Surgery May Be at Risk of Becoming Persistent Drug Users

SABCS 2020
Updated mo
2:25

Updated monarchE Trial Data Shows Abemaciclib Continues to Benefit Patients With High-risk, HR-positive, HER2-negative, Earlystage Breast Cancer

SABCS 2020

Videos from category: Respiratory

Resetting
7:38

Resetting the agenda: a new approach to asthma in GINA 2019

ERS 2019
Personalis
5:14

Personalised medicine applied to inhaler selection: Matching the patient with the right inhaler

ERS 2019
Severe ast
8:04

Severe asthma guidelines: Update 2019

ERS 2019
Treatment
2:18

Treatment with long term, low dose antibiotic could help people born with chronic lung condition

ERS 2019

Suggested videos

By Author
By Topic
By Congress
13:09
A Polypill for Primary Prevention of Cardiovascular Disease in Intermediate Risk People: Results of the International Polycap Study (TIPS)-3
AHA 2020
7:07
KEYNOTE-024 5-year OS update: first-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumor proportion score (TPS) ≥50%
ESMO 2020
6:13
Breast cancer highlights from ESMO2020
ESMO 2020
11:15
EXPLORER-HCM: Efficacy and Safety of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
ESC 2020
7:44
Summary of clinical and scientific topics discussed at EASD 2020 congress
EASD 2020
9:01
A Three-arm N-of-1 Trial With Statin, Placebo and Tablet Free Periods, to Verify Side Effects and Identify Their Cause: The SAMSON Trial
AHA 2020
8:34
State of the Science: The Six Pillars of Heart Failure Therapy
AHA 2020
11:06
IMpassion031: Results from a phase III study of neoadjuvant atezolizumab + chemotherapy in early triple-negative breast cancer
ESMO 2020
20:34
Triple negative breast cancer highlights in ESMO 2020
ESMO 2020
14:31
ESC Gold Medal 2020 Winner: Kari Stefansson
ESC 2020
15:58
2021 ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease
ESC 2020
6:12
Persistence and cardiovascular outcomes with ramipril, atorvastatin, ASA as a single pill compared to the multi pill combination. A subanalysis of the START study, a claims data analysis
ESC 2020
13:30
First-line nivolumab + ipilimumab combined with 2 cycles of platinum-based chemotherapy vs 4 cycles of chemo in advanced non-small cell lung cancer: Patient-reported outcomes from CheckMate 9LA
ESMO 2020
6:22
Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study
ASH 2019
10:47
Current state of frontline immunotherapy options in the treatment of mNSCLC and the effect of COVID-19 pandemic on lung cancer management
ESMO 2020
4:18
BPLTTC - Blood Pressure Lowering for Prevention of Cardiovascular Events across Different Levels of Blood Pressure
ESC 2020
4:34
Late-Breaking Science at ESC 2019 (Hot Line Session 1)
ESC 2019
9:11
Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study
EHA 2020
6:36
New non-allergenic, anti-inflammatory fragrance could be game changer for dry skin sufferers
EADV 2020
21:16
EORTC 1325-MG/Keynote 054 phase 3 trial
ESMO 2020
7:48
Allergy-related diseases and IBS
UEG 2020
7:33
2020 ESC Guidelines on Adult Congenital Heart Disease
ESC 2020
18:11
Nivolumab plus chemotherapy versus chemo as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: First results of the checkmate 649 study
ESMO 2020
13:26
From Trials to Bedside: Filling the Gaps in Implementing Evidence-based Care
AHA 2020
5:52
Postmenopausal Women With Early-stage Breast Cancer and Low Recurrence Score Could Skip Adjuvant Chemotherapy
SABCS 2020
9:22
MONARCH-E trial: Abemaciclib reduces recurrence in HR+ high risk early breast cancer
ESMO 2020
8:42
Safety and efficacy of the oral JAK3/TEC inhibitor PF-06651600 and the oral TYK2/JAK1 inhibitor PF-06700841 in a withdrawal/retreatment extension study in patients with alopecia areata
EADV 2019
6:02
An international randomized trial, comparing post-operative conformal radiotherapy to no PORT, in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement. Primary end-point analysis of Lung ART NCT00410683
ESMO 2020
8:36
Why We Should Still Care about Glycemic Lowering Strategies for Type 2 Diabetes
EASD 2019
Search by Scientific Content
Search by Congress
Search:
Date
Filters:
Global Per
8:14
Title Description

Global Perspectives on Breast Cancer Care during the COVID-19 Pandemic how BC was managed and lessons Learned

Presenter: Lidia Schapira
Oncology
SABCS 2020
Effect of
4:54
Title Description

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin on Patients with Relapsed/Refractory Classical Hodgkin Lymphoma: Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

Presenter: John Kuruvilla
Hematology
ASH 2020
Optimal Du
3:55
Title Description

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Presenter: Dennis Kim
Hematology
ASH 2020
Novelties
8:45
Title Description

Novelties on the treatment of Multiple Myeloma and Plasma Cell Disorders

Presenter: Joseph Mikhael
Hematology
ASH 2020
Omitting R
5:14
Title Description

Omitting Radiation Therapy After Breast-Conserving Surgery May Not Impact 10-year Survival Rates for Older Patients With HR-positive Breast Cancer

Presenter: Ian Kunkler
Oncology
SABCS 2020
Comprehens
14:08
Title Description

Comprehensive summary of novel multiple myeloma data from ASH2020

Presenter: Andrzej Jakubowiak
Hematology
ASH 2020
Women Who
5:46
Title Description

Women Who Undergo Mastectomy and Reconstructive Surgery May Be at Risk of Becoming Persistent Drug Users

Presenter: Jacob Cogan
Oncology
SABCS 2020
Comparison
7:32
Title Description

Comparison of Gilteritinib and Salvage Chemotherapy in FLT3-Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial

Presenter: Amer Zeidan
Hematology
ASH 2020
Polatuzuma
5:05
Title Description

Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

Presenter: Giuseppe Gritti
Hematology
ASH 2020
From Trial
13:26
Title Description

From Trials to Bedside: Filling the Gaps in Implementing Evidence-based Care

Presenter: Paul Whelton
Cardiology
AHA 2020
Updated mo
2:25
Title Description

Updated monarchE Trial Data Shows Abemaciclib Continues to Benefit Patients With High-risk, HR-positive, HER2-negative, Earlystage Breast Cancer

Presenter: Priya Rastogi
Oncology
SABCS 2020
Highlights
9:15
Title Description

Highlights of the Late-Breaking Abstracts Session of ASH 2020

Presenter: Christopher Flowers
Hematology
ASH 2020
Ruxolitini
5:24
Title Description

Ruxolitinib Vs Best Available Therapy in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease: Primary Findings from the Phase 3, Randomized REACH3 Study

Presenter: Robert Zeiser
Hematology
ASH 2020
What are t
3:32
Title Description

What are the trends in lymphoma therapy?

Presenter: Catherine Diefenbach
Hematology
ASH 2020
Effects of
11:38
Title Description

Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial

Presenter: Darrell Triulzi
Hematology
ASH 2020
A Multi-Ce
3:33
Title Description

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplan

Presenter: Corey Cutler
Hematology
ASH 2020

Lectures

Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients.

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology